Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting

NEW YORK–(BUSINESS WIRE)– Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical
company focused on bringing life saving hospital-based treatment to
people affected by central nervous system (CNS) related edema, today
announced that results from its Phase 2 trial of CIRARA™ for preventing
edema (brain swelling) in large hemispheric infarctions will be
presented during two oral presentations at the 68^th annual
American Academy of Neurology (AAN) meeting, the world’s largest
gathering of neurologists, bringing together more than 10,000 neurology
professionals across the globe. This year’s weeklong meeting will take
place April 15-21 in Vancouver, BC.

The two oral presentations will be conducted by principal investigators
and leading neuroscience researchers at Yale University and
Massachusetts General Hospital. Details for the two oral presentations
include:

Session Title: Stroke Clinical Trials
Title of Talk: GAMES
(Glyburide Advantage in Malignant Edema and Stroke) RP: A Phase II Study
Toward Preventing Edema After Ischemia
Presenting Author: Kevin N.
Sheth, MD, FAHA, FCCM, FNCS, FAAN, FANA, Associate Professor of
Neurology and of Neurosurgery; Division Chief, Neurocritical Care and
Emergency Neurology; Director, Neuroscience ICU W. Taylor Kimberly, MD,
PhD., Associate Director, Neuroscience Intensive Care Unit; Associate
Director, Neuroscience Intensive Care Unit; Massachusetts General
Hospital; Assistant Professor of Neurology; Harvard Medical School,
Boston, MA
Session Date: 4/16/2016
Session Time: 3:30 PM –
5:30 PM
Presentation Start: 4:45 PM
Duration: 15 minutes

Session Title: Neurocritical Care and Neuroscience Crossroads: From
Bench To Bedside Title of Talk: GAMES (Glyburide Advantage in Malignant
Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as
Proof-Of-Concept
Presenting Author: W. Taylor Kimberly, MD, PhD.,
Associate Director, Neuroscience Intensive Care Unit; Associate
Director, Neuroscience Intensive Care Unit; Massachusetts General
Hospital; Assistant Professor of Neurology; Harvard Medical School,
Boston, MA
Session Date: 4/20/2016
Session Time: 1:00 PM –
5:30 PM
Presentation Start: 3:00 PM
Duration: 15 minutes

In addition to the two podium presentations, there will a poster
presentation during the Neurocritical Care and Neuroscience Crossroads
Session on Wednesday, April 20 at 3:00 p.m., and a poster presented
along with 5-minute oral presentation in the Neurocritical Care and
Neuroscience Crossroads Session on Wednesday, April 20 at 4:10 p.m.

“Edema is one of the most significant mortality risks associated with
large hemispheric infarction and other acute CNS conditions,” comments
Sven Jacobson, CEO of Remedy Pharmaceuticals. “For instance, in the
first week following LHI, 78% of all deaths are attributable to edema
and in hemorrhagic stroke, 93% of deaths are caused by this type of
swelling. CNS edema continues to be a condition characterized by major
unmet medical need. We look forward to beginning our phase 3 study in
CIRARA, CHARM, later this year.”

ABOUT THE CHARM TRIAL AND LHI

CHARM (Cirara in large Hemispheric infarction Analyzing modified Rankin
& Mortality) is a phase 3 trial in stroke patients with large
hemispheric infarctions (LHI). LHI, also known as malignant middle
cerebral infarction, is a devastating disease associated with
significant disability and mortality. Brain swelling occurs as a result
of loss of function of membrane transporters, causing sodium and water
influx into the necrotic or ischemic cell, leading to cytotoxic edema.
Unrelenting swelling disrupts the blood-brain barrier leading to
vasogenic edema. The risk of subsequent neurological deterioration and
death is high, 40% to 80%.

ABOUT CIRARA

CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels,
which are upregulated following ischemia and trauma. Opening of these
channels can lead to damage and death of the blood brain barrier, and
subsequent edema. Sur1-Trpm4 channels were discovered by University of
Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board
member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous
delivery at the bedside or even in an ambulance. CIRARA uses our
proprietary, patented MPD™ technology. CIRARA is an investigational drug
and is not approved by FDA.

ABOUT REMEDY PHARMACEUTICALS

Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage
pharmaceutical company focused on developing and bringing lifesaving
treatment to millions of people affected by acute central nervous system
(CNS) edema – including large hemispheric infarction and moderate/severe
traumatic brain injury, as well as other ischemic injuries and
neurological disorders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160412005200/en/